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Summan Somatic allelic loss is regarded as a hallmark of tumour-suppressor gene (TSG) inactivation.
Thirtv-one human bladder transitional cell carcinomas (TCCs) were examined for allelic loss at five
chromosome 18q loci. including the DCC gene (deleted in colorectal carcinoma) and at chromosome lIplS in
a restriction fragment length polymorphism analysis. Allelic loss was observed at one or more 18q loci in 9 26
(35°o) samples. associated with muscle-invasive disease (P<0.02). Allelic loss was observed at DCC in 8 24
(33O0) samples. associated With muscle-invasive disease (P = 0.05). Three out of the five evaluable recurrent
TCCs exhibited allelic loss at DCC. tw-o of which were superficial. No allelic losses were detected at other 18q
loci in tumours which retained both DCC alleles. Allelic loss was observed at lIp15 in 5 20 (250o) tumours.
These data suggest the presence of a late-acting TSG located on 18q in TCC bladder cancer. DCC is a
candidate gene since it lies within the region of most common deletion (18q21.3-qter).
Multistage epithelial carcinogenesis is considered to result
from an accumulation of somatic genetic abnormalities in-
cluding the inactivation of tumour-suppressor genes (TSG)
and the activation of cellular proto-oncogenes. TSGs are a
heterogeneous group of genes whose inactivation may result
in deregulated growth and clonal expansion or the acquisi-
tion of invasive or metastatic potential (Brewster et al..
1992). In clinical oncology. TSGs or their products may be
exploited as screening tools for inherited cancers, as prognos-
tic indicators and potentially as targets for corrective gene
therapy (Brewster & Simons, 1994).
Non-random loss of chromosomal regions occurs fre-
quently in neoplasia (Mitelman et al., 1991). Although loss of
chromosome regions of less than 25% of tumour samples
may be considered random and of questionable significance
(Seizinger et al.. 1991). clonal somatic allelic loss is con-
sidered to be a hallmark of TSG inactivation since the loss
can unmask a 'recessive' mutant allele (Cavenee et al.. 1983).
Somatic allelic loss may be demonstrated as loss of
heterozygosity (LOH) by restriction fragment length poly-
morphism (RFLP) analysis of paired constitutional and
tumour DNA.
The DCC gene (deleted in colorectal carcinoma) (Fearon
et al.. 1990) maps to chromosome 18q21.3. spanning >3 Mb
to include at least 29 exons. The predicted DCC protein
shows sequence homology with neural cell adhesion
molecules and other cell-surface glycoproteins; it is suggested
that DCC plays a role in maintaining cell-cell interaction.
18q LOH occurs in over 70% of colorectal carcinomas, 47%
of advanced adenomas and less than 15% of earlier
adenomas (Vogelstein et al.. 1988). In addition. LOH at
DCC has been observed in 610% of gastric cancers (Uchino et
al.. 1992). 31% of breast cancers (Thompson et al.. 1993).
44% of ovarian cancers (Chenevix-Trench et al., 1992) and
26% of prostate cancers (Brewster et al.. 1994). Deletion
mapping data from the last two studies have suggested the
presence of a second TSG located telomeric to DCC on
chromosome 18q.
Bladder cancer caused 5.659 deaths in the UK in 1992.
ranking fifth (males) and 11th (females) in terms of cancer-
related mortality (CRC Education Department. personal
communication). Over 95% of all bladder cancers in indus-
trialised countries are transitional cell carcinomas (TCCs).
RFLP studies of TCC have shown frequent ( > 5000) LOH
on chromosome 9q (Tsai et al.. 1990: Cairns et al.. 1993). It
has been proposed that an early-acting TSG resides on 9q.
since LOH is often the only genetic abnormality observed in
superficial papillary TCC. In invasive TCC. LOH has been
observed at llpl5 in 33-42% samples (Fearon et al.. 1985:
Tsai et al.. 1990: Presti et al.. 1991). but similarly a TSG
remains to be identified here. LOH within the retinoblastoma
susceptibility gene (Rbl) gene (13ql4) was observed in 56%
of muscle-invasive samples (Cairns et al.. 1992). on 17p in
50-810% of muscle-invasive samples (Tsai et al.. 1990:
Habuchi et al.. 1993) and at a locus (18q22) distal to DCC in
4 12 (33%) muscle-invasive samples. but in 0 5 superficial
tumours (Presti et al.. 1991). Dalbagni et al. (1993) reported
LOH on 18q in 26% of TCCs. Reznikoff et al. (1993) have
developed a system in which transformation and other neo-
plastic characteristics of cultured immortalised human
urothelial cells may be studied by exposing the cells to car-
cinogens such as 4-aminobiphenyl. Among other changes.
18q deletions were observed by RFLP analysis of derivative
tumours in nude mice.
Here we present the results of an RFLP analysis in which
DNA from a series of TCCs was studied for allelic loss at
five chromosome 18q loci including DCC (Figure 1). aiming
to define a region of common deletion and. furthermore. its
relationship to DCC. In order to provide a comparison
between our sample population and those of previous
studies. we chose to examine our series for allelic loss at
chromosome I Ip15.
Materials and methods
Tissues
Thirty-one TCCs were included in the analysis. consecutively
obtained from 20 men and 11 women. Ten were recurrent
tumours. Samples were transected longitudinally. half snap
frozen and stored at -70°C and half submitted for his-
tological examination. Those samples containing less than
70% malignant cells were excluded. Tumours were graded
histologically as GI-3 (World Health Organization classi-
fication) and pathologically staged by the TNM system
(Hunter. 1978). Herein. pTa indicates non-invasive superficial
papillary tumour: pTI indicates invasion of the lamina pro-
pna: and pT2-3 indicates muscle-invasive tumour. Addi-
tionally, 5 ml of heparinised venous blood was obtained from
each patient.
Correspondence: S.F. Brewster. Bnrstol Urological Institute. South-
mead Hospital. Bn'stol BSIO 5NB. UK.
Received 21 December 1993: and in revised form 5 April 1994.
Br. J. Cancer (1994). 70, 697-700 (E) Macmillan Press Ltd.. 1994698 S.F. BREWSTER et al.
DNA extraction and Southern blot hvbridisation analivsis
High molecular weight tumour and lymphocyte DNA was
extracted as described previously (Brewster et al., 1994).
Paired DNA samples were digested with Mspl, EcoRI, BglII,
PstI or HinJI and electrohoresed on 1% agarose gels.
Southern blots (Hybond N +. Amersham, UK) were hybrid-
ised to random-primer 32P-labelled DNA probes (Table I) in
rapid hybridisation buffer (Amersham) and washed to a final
stringency of either 2 x SSC,0.5% SDS or 0.5 x SSC0.1%
SDS at 65°C. Optical scanning densitometry of autoradio-
graphs was undertaken using a Biorad videodensitometer in
certain cases to investigate visual impressions of allelic loss.
LOH was considered present when one of two polymorphic
alleles present in lymphocyte DNA was reduced in the
tumour DNA by at least 50%, so making allowance for
genetic heterogeneity and contaminating normal DNA in
tumour samples. Samples showing LOH were subjected to
DNA 'fingerprinting' using a 720 bp minisatellite probe
(Jeffreys et al.. 1985).
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Figure 1 A schematic diagram of chromosome 18, showing the
relationship of DCC to the four anonymous 18q RFLP markers
used.
Table I DNA probes used to detect RFLPs
Restriction
Probe name Locus gene enzyme Reference
pL2.7 18q12.2 PstI Hofker et al. (1986)
OL VII A8 18q12.1-21.1 Mspl Delattre et al. (1987)
JOSH 4.4 18q21.3 DCC Pstl Simons et al. (1992)
SAM 1.1 18q21.3 DCC EcoRl Simons et al. (1992)
p15-65 18q21.3 DCC .spl Fearon et al. (1990)
pOS-4 I 8q22 Pstl Taql Nishisho et al. (1987)
pL159-1 18q23 Pstl Kazazian et al. (1986)
p2.1 I1pI5 Pstl Hinfl Brookes et al. (1989)
pEJ6.6 I1 pI5.5 .Uspi Krontiris et al. (1993)
Statistical analysis
The Fisher-Irwin exact chi-square (X) test applying Yates'
correction was used for statistical analysis of the results.
Results
Results for allelic status on chromosome 18q are summarised
in Table II. DNA fingerprinting confirmed tumour blood
identity in all but one sample exhibiting LOH; in this case
(tumour 5) insufficient DNA was available.
Chromosome 18q and DCC
In total, 26 31 (84%) tumours were evaluable at one or more
chromosome 18q locis, of which nine (35%) exhibited LOH.
correlating significantly with advanced pathological stage:
only 4/20 superficial (pTa pTl) tumours exhibited 18q allele
loss compared with 5 6 muscle-invasive (pT2 3) tumours
(=5.62. P=0.018).
Combining three RFLP markers for DCC. 24 (77%) sam-
ples were informative. LOH at DCC was observed in eight
(33%) tumours, examples of which are shown in Figure 2.
Five recurrent TCCs were informative at DCC. of which
three showed LOH: two were pTa and the other was pT2 3.
LOH at DCC was significantly associated with muscle
invasion, observed in 4 19 pTa pTl and 4 5 pT2 3 samples
(X2 = 3.82, P = 0.05), and muscle invasion or recurrence
(X:=4.2, P = 0.04), but non-significantly with all (pTl +
pT2 3) invasive disease (P = 0.3). grade 3 disease (P = 0.6) or
recurrent disease alone (P = 0.6).
Four out of eight tumours showing LOH at DCC
exhibited LOH at one of the two centromeric loci; two
tumours, 18 and 26. retained heterozygosity with at least one
of these markers. All evaluable tumours exhibiting LOH at
DCC also exhibited LOH telomeric to DCC. Tumour 21 was
evaluable at only one locus. centromeric to DCC. which
showed LOH. No tumour retaining heterozygosity at DCC
Table I Chromosome 18q allelic status in 31 TCCs
Tumour: grade stage 18q status
1 G2pTa No LOH
2 G2pTa No LOH
3 G2pTa R No LOH
4 G2pTa R NI
5 G2pTa LOH
6 G2pTa No LOH
7 G2pTa No LOH
8 GIpTa No LOH
9 GIpTa No LOH
10 G2pTa R NI
11 G2pTa R NI
12 G2pTa R No LOH
13 G2pTa No LOH
14 G2pTa No LOH
15 G2pTa R LOH
16 GlpTa No LOH
17 G2pTa R LOH
18 G2pTl LOH
19 G3pT2/3 R NI
20 G3pT2/3 LOH
21 G3pT2,'3 LOH
22 G2pT2 3 LOH
23 G3pTI No LOH
24 G2pTl No LOH
25 G2pT2/'3 R NI
26 G3pT2,3 LOH
27 G3pTI No LOH
28 G3pT2/3 NI
29 G2pT2 3 No LOH
30 G3pT2 3 LOH
31 G3pTl No LOH
LOH, loss of heterozygosity; NI, not informative; R, recurrent
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showed LOH elsewhere on 18q; the region of commonest
deletion in this series was therefore 18q21.3-qter (Table III).
Chromosome Ilp
Twenty out of 24 (82%) tumours were informative with one
of the two llpl5 markers. of which five (25%) exhibited
LOH (Figure 3). This alteration was observed in 1 9 (11%)
pTa and 4 11 (36%) invasive (pT1-3) tumours; this was not
statistically significant (/ =0.61, P=0.44). There were no
statistically significant associations between llpl5 LOH and
muscle-invasive, recurrent or G3 disease (P = 0.42. P1, P = I
respectively).
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Figure 3 Autoradiograph showing LOH at lIp15 in tumour 31.
B = blood. T = tumour. A = allele.
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Figre 2 Autoradiographs showing LOH at DCC (a) in tumour
22, (b) in tumour 15 and (c) in tumour 18. B =blood,
T = tumour, A = allele.
The theory of multistep carcinogenesis (Nordling. 1953) was
given a molecular basis by the demonstration of an
accumulation of genetic events resulting in the activation of
oncogenes and the loss of TSGs in colorectal tumours of
increasing grade and stage (Fearon & Vogelstein, 1990).
There is mounting evidence that the clinicopathological
course of bladder cancer is governed by such an accumula-
tion. The sequence of events appears to be initially associated
with loss of genetic material on chromosome 9q; the invasive
phenotype is associated with losses on 1lp and subsequently
on 3p, 13q, 17p and 18q, though many of the pivotal genes,
including those on llp and 18q, remain unidentified. Com-
binations of these alterations may confer upon tumours the
various behavioural phenotypes which characterise the
clinical heterogeneity of invasive bladder cancer (Prout et al..
1979).
Multifocality and recurrence are common clinical features
of TCC: 70% of Gl and 80-90% of G3 superficial tumours
recur after first resection, of which 10-15% will have become
invasive. Two theories on the pathogenesis of these
phenomena have been proposed. Traditionally, it was held
that an inherent or environmental factor rendered the entire
urothelium unstable, from renal calyces to prostatic urethra.
This 'field change' may explain why patients develop upper
urinary tract TCC many years after bladder TCC has been
diagnosed and treated. Alternatively, TCC can be viewed as
a monoclonal disease with a great propensity to seed. X
chromosome inactivation and other somatic allelic changes
within 13 TCCs from four patients support this theory (Sid-
ranksy et al., 1992). All tumours belonging to the same
patient exhibited identical X chromosome inactivation, while
normal surrounding transitional cells exhibited random X
inactivation. In addition, each evaluable tumour from a given
patient exhibited loss of identical 9q alleles but variable 17p
and 18q alleles, suggesting that the latter changes occur later
during the independent evolution of individual 'multifocal'
tumours. Recurrent tumours may also appear by this seeding
mechanism.
In the present study, allelic loss on chromosome 18q was
Table III Chromosome I8q allelic deletion mapping
pL2.7 (8) OLVIIA8 (18j SAM. 1. (15) JOSH4.4 (19) p15-65 (16) pOS-4 (9) pL 159-I (11}
Probe (total informative) 18q12.2 18ql2.1-21.1 DCC: 18q213 DCC: 18q21.3 DCC: 18q21.3 18q22 18q23
Tumour: grade, stage
5 G2pTa NI LOH LOH LOH Ni Ni LOH
15 G2pTa R NI LOH LOH LOH Ni Ni LOH
17 G2pTa R NI LOH LOH LOH LOH LOH NI
18 G2pTI No LOH No LOH - LOH Ni LOH NI
20 G2pTa R LOH Ni - LOH LOH - LOH
21 G3pT2 3 NI LOH NI NI NI NI NI
22 G2pT2 3 R NI NI LOH LOH LOH LOH LOH
26 G3pT2 3 NI No LOH LOH LOH Ni LOH NI
30 G3pT2 3 LOH Ni LOH LOH LOH NI NM
LOH, loss of heterozygosity; NI. not informative; R. recurrent tumour.700 S.F. BREWSTER et al.
observed in one-third of informative TCCs. significantly
associated with muscle invasion. This is slightly (but not
significantly) more frequent than previously reported (Presti
et al.. 1991: Dalbagni et al.. 1993). Two explanations are
offered. First. only the anonymous probe pOS4. mapping
telomeric to DCC. was used in previous studies. Second. it is
not clear from either previous study whether any non-
invasive TCC samples were recurrent. Two of the three pTa
TCCs exhibiting 18q LOH in the present study were recur-
rent and, as a group. recurrent and or muscle-invasive
disease was significantly associated with this event. DCC was
included in the deleted regions of all the tumours exhibiting
allelic loss on 18q. The region of commonest deletion was
18q21.3-qter: no interstitial 18q deletions were observed.
One-quarter of TCCs studied exhibited loss of llpl5 alleles.
This change was observed in tumours of all stages. increasing
with grade and stage at a slightly (but not significantly) lower
frequency than previous observations of lIp LOH (see ear-
lier). We conclude from this that our sample tumour popula-
tion is comparable to those of previous studies.
A suppressor role for DCC in bladder cancer is supported
by preliminary studies of 18q-deleted TCC cells in culture. in
which DCC expression was undetectable (C.A. Reznikoff,
American Society of Basic Urological Research Annual
meeting, 1993, and personal communication). Following
transfection with DCC cDNA, reversion of malignant
phenotype and detectable DCC transcript was observed in
these cells. Similar suppression was not observed when these
cells were transfected with mutant DCC cDNA under the
same conditions.
It is concluded that loss of genetic material on 18q21.3-
qter, a region including DCC. is associated with muscle-
invasive disease and occurs frequently in recurrent disease.
DCC is therefore a potential target for 18q deletion and is
thus a candidate TSG in TCC.
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